For the quarter ending 2025-09-30, KROS had $3,257K increase in cash & cash equivalents over the period. $3,117K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total segment revenue | 14,262 | - |
| Research and development-KER065Program Expenses | 1,345 | - |
| Research and development-Elritercept Program Expenses | 3,341 | - |
| Research and development-Cibotercept Program Expenses | 1,218 | - |
| Research and development-Preclinical Development Expenses | 1,700 | - |
| Compensation costs (excluding stock based compensation) | 9,568 | - |
| Stock-based compensation | 3,986 | - |
| Depreciation expense | 395 | - |
| Other segment items | 8,346 | - |
| Dividend income | 6,933 | - |
| Income tax (provision) benefit | -1,424 | - |
| Net income (loss) | -7,280 | 117,755 |
| Depreciation expense | 395 | 714 |
| Gain on disposal of fixed asset | 0 | 14 |
| Stock-based compensation expense | 3,986 | 17,405 |
| Non-cash lease expense | 609 | 1,179 |
| Accounts receivable | -12,324 | 13,074 |
| Prepaid expenses and other current assets | -4,434 | 557 |
| Other assets | 0 | -2,056 |
| Accounts payable | -2,955 | 651 |
| Right-of-use assets and operating lease liabilities | 525 | 907 |
| Deferred revenue | -770 | 925 |
| Current tax liability | -2,174 | 6,321 |
| Accrued expenses and other current liabilities | -4,795 | -906 |
| Net cash provided by (used in) operating activities | 3,249 | 131,548 |
| Purchase of property and equipment | 132 | 1,285 |
| Net cash used in investing activities | -132 | -1,285 |
| Proceeds from issuance of common stock-Secondary Offering | 0 | 0 |
| Payment of issuance costs | 0 | 0 |
| Proceeds from issuance of common stock-At The Market Offering | 0 | 0 |
| Payment of issuance costs associated with issuance of common stock under the atm agreement-At The Market Offering | 0 | 0 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 138 | - |
| Proceeds from exercise of stock options | 2 | 21 |
| Net cash provided by financing activities | 140 | 21 |
| Net increase in cash, cash equivalents and restricted cash | 3,257 | 130,284 |
| Cash and cash equivalents at beginning of period | 561,380 | - |
| Cash and cash equivalents at end of period | 694,921 | - |
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)